Timothy Craig, DO

It was with pleasure that we had the opportunity to review a manuscript written by our colleagues titled “Challenges in the management of hereditary angioedema in urban and rural settings: Results of a United States survey.”

SAN ANTONIO — Sebetralstat significantly reduced cumulative hereditary angioedema attack and symptom severity compared with placebo, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Lanadelumab prevented hereditary angioedema attacks among patients aged 2 to younger than 12 years with no serious adverse events, according to a study presented at European Academy of Allergy and Clinical Immunology Hybrid Congress.